{"protocolSection":{"identificationModule":{"nctId":"NCT01233986","orgStudyIdInfo":{"id":"ABYSS"},"organization":{"fullName":"Hallym University Medical Center","class":"OTHER"},"briefTitle":"Association of Apolipoprotein B-48 Level and Large arterY Atherosclerotic iSchemic Stroke(ABYSS)","officialTitle":"Prospective, Matched Case Control, Multicenter, Observational Study for the Association of Serum Apolipoprotein B-48 Level and Large arterY Atherosclerotic iSchemic Stroke(ABYSS)"},"statusModule":{"statusVerifiedDate":"2010-11","overallStatus":"UNKNOWN","lastKnownStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-05"},"primaryCompletionDateStruct":{"date":"2011-03","type":"ACTUAL"},"completionDateStruct":{"date":"2011-10","type":"ESTIMATED"},"studyFirstSubmitDate":"2010-10-21","studyFirstSubmitQcDate":"2010-11-02","studyFirstPostDateStruct":{"date":"2010-11-04","type":"ESTIMATED"},"lastUpdateSubmitDate":"2011-10-04","lastUpdatePostDateStruct":{"date":"2011-10-05","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hallym University Medical Center","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate whether the serum apoB48 level is associated with atherosclerotic ischemic stroke."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"],"keywords":["Acute Ischemic Stroke","Atherosclerosis","Apolipoprotein B48"]},"designModule":{"studyType":"OBSERVATIONAL","designInfo":{"observationalModel":"CASE_CONTROL","timePerspective":"PROSPECTIVE"},"bioSpec":{"retention":"SAMPLES_WITHOUT_DNA","description":"Serum level of apolipoprotein B-48"},"enrollmentInfo":{"count":112,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Case group - Large artery atherosclerosis"},{"label":"Control group-Small vessel occlusion"}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The serum level of fasting apolipoprotein B-48","timeFrame":"72 hours within stroke onset"},{"measure":"The serum level of postprandial apolipoprotein B-48","timeFrame":"within 72 hours after stroke onset"}],"secondaryOutcomes":[{"measure":"The serum level of the postprandial triglyceride","timeFrame":"72 hours within stroke onset"},{"measure":"The serum level of fasting total cholesterol","timeFrame":"within 72 hours after stroke onset"},{"measure":"The serum level of fasting LDL cholesterol","timeFrame":"within 72 hours after stroke onset"},{"measure":"the level of fasting HDL cholesterol","timeFrame":"within 72 hours after stroke onset"},{"measure":"the level of fasting triglyceride","timeFrame":"within 72 hours after stroke onset"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nLarge artery atherosclerotic ischemic stroke group(LAA group)\n\n* Age over 20 years\n* Patients with symptomatic stenosis in the eligible vessels(the middle cerebral artery, anterior cerebral artery, or internal carotid artery) as assessed by MRA or CTA corresponding to the acute ischemic stroke\n* Patients without the occlusion of corresponding artery by MRA or CTA\n* The fasting and postprandial serum Apo B-48 level can be assessed within 72 hours after the symptom onset of ischemic stroke\n\nSmall vessel occlusive ischemic stroke group (SVO group)\n\n* Age over 20 years\n* Patients with acute ischemic stroke of basal ganglia, internal capsule, or corona radiata\n* Patients without both symptomatic and asymptomatic arterial occlusion or stenosis by MRA or CTA\n* Patients without a history of systemic atherosclerosis(for example, acute myocardial infarction, angina, peripheral arterial disease, aortic aneurysm)\n* The fasting and postprandial serum Apo B-48 level can be assessed within 72 hours after the symptom onset of ischemic stroke\n\nExclusion Criteria: both LAA group and SVO group\n\n* Patients with cardioembolic ischemic stroke\n* Patients treated with lipid lowering agents or steroid within the previous 30 dsys\n* Patients with severe liver disease (AST \\>100 or ALT \\>100) at the time of randomization\n* Patients with endocrine disease except diabetes mellitus at the time of randomization (for example, thyroid disease, adrenal disease)\n* Patients with severe renal disease (serum creatinine \\>2.0mg/dl)at the time of randomization\n* chronic alcoholics or drug user\n* Patients with infection at the time of randomization\n* Patients, in the opinion of the investigator, unlikely to comply with the clinical study or unsuitable for the any other disease or reason\n* Informed consent has not been obtained","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Tertiary Hospital","samplingMethod":"PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Byung-Chul Lee, MD, PhD","role":"CONTACT","phone":"+82-31-380-3741","email":"ssbrain@hallym.ac.kr"},{"name":"Kyung-Ho Yu, MD, PhD","role":"CONTACT","phone":"+82-31-380-3743","email":"ykh1030@hallym.ac.kr"}],"overallOfficials":[{"name":"Byung-Chul Lee, MD,PhD","affiliation":"Hallym University Medical Center","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Hallym University Sacred Heart Hospital","status":"RECRUITING","city":"Anyang","country":"Korea, Republic of","contacts":[{"name":"Byung-chul Lee, MD,PhD","role":"CONTACT","phone":"+82-31-380-3741","email":"ssbrain@hallym.ac.kr"},{"name":"Kyung-Ho Yu, MD, PhD","role":"CONTACT","phone":"+82-31-380-3743","email":"ykh1030@hallym.ac.kr"},{"name":"Mi Sun Oh, MD","role":"SUB_INVESTIGATOR"}],"geoPoint":{"lat":37.3925,"lon":126.92694}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M25878","name":"Atherosclerosis","relevance":"LOW"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}